Embecta Corp. (NASDAQ:EMBC – Get Free Report) CEO Devdatt Kurdikar bought 30,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was bought at an average cost of $4.70 per share, for a total transaction of $141,000.00. Following the completion of the transaction, the chief executive officer directly owned 804,919 shares of the company’s stock, valued at $3,783,119.30. This trade represents a 3.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Embecta Stock Performance
Shares of EMBC opened at $5.10 on Friday. Embecta Corp. has a 1 year low of $2.77 and a 1 year high of $15.55. The company has a market cap of $288.97 million, a price-to-earnings ratio of 3.45 and a beta of 0.81. The firm has a fifty day moving average of $3.50 and a 200-day moving average of $6.41.
Embecta (NASDAQ:EMBC – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.27 by $0.29. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The business had revenue of $271.70 million during the quarter, compared to analyst estimates of $254.53 million. During the same quarter in the prior year, the firm earned $1.12 earnings per share. The company’s quarterly revenue was down 8.1% on a year-over-year basis. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Analysts predict that Embecta Corp. will post 1.84 EPS for the current year.
Embecta Announces Dividend
More Embecta News
Here are the key news stories impacting Embecta this week:
- Positive Sentiment: CEO Devdatt Kurdikar, CFO Jacob Elguicze and director Jeffrey Z. Mann collectively purchased 70,000 shares worth approximately $334,200 on August 12. The insider buying could signal that management and the director believe Embecta’s shares are undervalued after their steep decline. SEC insider transaction filing
- Neutral Sentiment: Embecta also disclosed a quarterly dividend of $0.01 per share, or $0.04 annualized, with a yield of roughly 0.8%. The modest payout is unlikely to be a major near-term stock catalyst but may appeal to income-focused investors. Embecta dividend and insider trading report
- Neutral Sentiment: Multiple law firms, including Hagens Berman, Bronstein Gewirtz & Grossman, Kaplan Fox, Faruqi & Faruqi and Rosen, reminded investors that August 17 is the deadline to seek lead-plaintiff status. The notices target investors who purchased EMBC securities between November 25, 2025, and May 4, 2026, and mostly repeat previously reported information. Hagens Berman class action deadline notice
- Negative Sentiment: The underlying securities class action alleges that Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business and issued misleading fiscal 2026 guidance. If the claims gain traction, the company could face legal expenses, reputational damage and further questions about management credibility. The allegations have not been proven in court. Hagens Berman lawsuit alert
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on EMBC. Wall Street Zen cut Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Zacks Research raised Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. BTIG Research cut Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Weiss Ratings downgraded Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Finally, Mizuho reduced their price target on Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Three equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Embecta has a consensus rating of “Reduce” and a consensus price target of $11.00.
Check Out Our Latest Analysis on Embecta
Institutional Trading of Embecta
Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC increased its stake in shares of Embecta by 138.4% during the first quarter. SG Americas Securities LLC now owns 1,038,948 shares of the company’s stock valued at $9,184,000 after acquiring an additional 603,106 shares during the period. Walleye Capital LLC bought a new stake in Embecta during the first quarter worth approximately $7,013,000. Universal Beteiligungs und Servicegesellschaft mbH lifted its position in Embecta by 1,068.0% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 143,616 shares of the company’s stock worth $1,708,000 after purchasing an additional 131,320 shares during the period. UBS Group AG lifted its position in Embecta by 200.8% in the fourth quarter. UBS Group AG now owns 630,994 shares of the company’s stock worth $7,496,000 after purchasing an additional 421,254 shares during the period. Finally, LSV Asset Management lifted its position in Embecta by 92.5% in the fourth quarter. LSV Asset Management now owns 552,582 shares of the company’s stock worth $6,565,000 after purchasing an additional 265,482 shares during the period. 93.83% of the stock is currently owned by institutional investors.
Embecta Company Profile
Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.
The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.
Featured Articles
- Five stocks we like better than Embecta
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
